Live Updates > Live Update Details
2025-07-29 14:51:13
[Hanlin's share price soared 4.9% to a record high, and its biosimilars received positive review from the EU] 1. The share price of Hanlin (2696.HK), a biopharmaceutical company under Fosun Pharma Group (2196.HK/600196.SS), rose 4.9% on Tuesday, setting a new record since its listing in 2019. 2. The rise in share price stems from the company's announcement that its developed biosimilar HLX14 received a positive review opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, which recommended approval of the drug's marketing application. 3. HLX14 is a biosimilar to Amgen's original drug denosumab, mainly used for the treatment of osteoporosis. 4. Since the beginning of this year, Hanlin's share price has increased by 204.6%, far exceeding the 26.4% increase in the Hang Seng Index during the same period. Driven by this, the Hang Seng Hong Kong Listed Biotech Index had a maximum intraday increase of 3.6% that day.
